Physician profile
Adam Spjute
NPI 1265851232
$23,214.54
in general payments reported to CMS, 2019-2025
19 companies · $9,533 in 2025
The $9,533 reported for 2025 was more than what 94% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $647 · 2020: $199 · 2021: $1,434 · 2022: $3,091 · 2023: $2,620 · 2024: $5,691 · 2025: $9,533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,543 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,400 · Travel and Lodging: $4,154 · Consulting Fee: $2,748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,542.65 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,400.00 |
| Travel and Lodging | $4,153.77 |
| Consulting Fee | $2,747.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $19,837.42 | 2021-2025 | Proclaim, Octrode, Infinity |
| Relievant Medsystems, INC. | $1,396.52 | 2022-2023 | Intracept |
| Abbvie INC. | $485.30 | 2021-2024 | Ubrelvy, Qulipta |
| Nevro Corp. | $411.18 | 2019 | |
| Nalu Medical, INC. | $346.64 | 2020-2025 | Nalu Neurostimulation System |
| Boston Scientific Corporation | $281.84 | 2019-2024 | |
| Amgen INC. | $96.91 | 2020-2021 | |
| Medtronic, INC. | $81.28 | 2021-2024 | Synchromedii, Intellis Adaptivestim |
| Teva Pharmaceuticals USA, INC. | $52.44 | 2019-2020 | |
| Biodelivery Sciences International, INC. | $49.26 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $28.90 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $27.80 | 2021 | |
| Pfizer INC. | $26.11 | 2020-2024 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $19.83 | 2022 | |
| Stryker Corporation | $17.39 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grt US Holding, INC. | $16.82 | 2022 | |
| Collegium Pharmaceutical, INC. | $14.10 | 2020 | |
| Medtronic USA, INC. | $12.84 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.96 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Spjute listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.